Our Latest News - BUHLMANN

BUHLMANN News

Automate fecal Calprotectin and Pancreatic Elastase assay testing, with BÜHLMANN fCAL® turbo & fPELA® turbo US IVD application

BÜHLMANN fCAL® turbo or BÜHLMANN fPELA® turbo BÜHLMANN fCAL® turbo or BÜHLMANN fPELA® turbo currently have validated IVD application notes for use in the United States on the clinical chemistry analyzers listed below. These allow for the FDA 510(k) cleared fecal calprotectin or FDA Exempt fecal pancreatic elastase to be tested on the Roche cobas®
Continue Reading

LabSense News Q1 2021 Edition

In this "Q1 2021 Edition" we introduced the new fCAL turbo and fPELA application notes (eg. Vitros 5600, cobas® 501, AU480, ADVIA® and Atellica, to name a few). We also introduce the transfer of the founding Melatonin assays and highlight some significant publications to evolve food allergy testing and IBD testing with fecal calprotectin and
Continue Reading

BUHLMANN Diagnostic Corp – New Partner Channel Agreement with Roche Diagnostics

BUHLMANN Diagnostic Corp – New Partner Channel Agreement with Roche Diagnostics.

Continue Reading

LabSense News Q3 2020 Edition

In this “Q3 2020 Edition” we introduce two NEW BUHLMANN Products. The new FDA Exempt, fecal Pancreatic Elastase (fPELA®) turbo assay, as well newly developed Quantum Blue® 3 Reader (QB3).  Also watch the IBDoc® video ‘Want to improve care for IBD patients?’ and lastly watch Dr. Arne Roseth’s AMLI presentation “The latest on IBD Care
Continue Reading

Educational Webinar recording from AMLI presentation by Dr Arne Roseth

BÜHLMANN fCAL® ELISA is FDA 510(k) cleared.  For in vitro Diagnostic Use. Health Canada License: 80726 Abstract Inflammatory Bowel Disease (IBD) is a chronic inflammatory disease of the gut, which presents with periods of inflammatory activity (flares) and quiescent phases (remission) as can be seen in many chronic diseases. IBD includes several different diseases; the two most important
Continue Reading

BÜHLMANN anti-MAG autoantibodies ELISA Citations

US: BÜHLMANN GanglioCombi™ ELISA is for Research Use Only. Not for use in diagnostic procedures. Health Canada Licence: 100436 and 100476 The citation list should be used for information only. Boscarino M et al., 2020: Spinal Cord Impairment in anti-MAG Neuropathy: Evidence from Somato-sensory Evoked Potentials. Brain Sci. 10(282); 1-10 DOI: 10.3390/brainsci10050282 Continue Reading Colchester
Continue Reading

BÜHLMANN anti-SGPG autoantibodies ELISA Citations

US: BÜHLMANN GanglioCombi™ ELISA is for Research Use Only. Not for use in diagnostic procedures. Health Canada Licence: 100436 and 100476 The citation list should be used for information only. Herrendorff R et , 2017: Selective in vivo removal of pathogenic anti-MAG autoantibodies, an antigen specific treatment option for anti-MAG neuropathy. PNAS, www.pnas.org/cgi/doi/10.1073/pnas.1619386114 DOI: 10.1073/pnas.1619386114
Continue Reading

BÜHLMANN anti Ganglioside antibodies Citations

US: BÜHLMANN GanglioCombi™ ELISA is for Research Use Only. Not for use in diagnostic procedures. Health Canada Licence: 100436 and 100476 The citation list should be used for information only. Toscano G et al., 2020; Guillain-Barré Syndrome Associated with SARS-CoV-2 (Letter to the editor); NEJM; April 27, 2020 DOI: 10.1056/NEJMc2009191 Continue Reading Delmont E et
Continue Reading

Smartphone-based Health Applications IBDsmart and Doc®

McCombie A. et al., A non-inferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and Doc® in the care of IBD patients, Inflamm Bowel Dis, 2019 Highlights from this Publication "Remote symptom and fecal calprotectin monitoring is effective and acceptable. It also reduces the need for face-to-face outpatient appointments." Read Citation
Continue Reading

fecal Calprotectin as a Substitute for Routine Laboratory Analysis

Hejl et al.; Point of care testing of fecal calprotectin as a substitute for routine laboratory analysis. Practical Laboratory Medicine, 2017 Highlights from this Publication "This study suggests that IBDoc® is a suitable alternative for the assessment of disease activity in IBD patients." Read Citation Health Canada License: 98903 US: Not available for sale in
Continue Reading